Emerging roles for B-lymphocytes in type 1 diabetes
Self reactive B lymphocytes play two main pathological roles in autoimmune diseases: as secretors of autoantibodies and as specialised antigen-presenting cells that present self-components to autoreactive T lymphocytes. In recognition of these roles, recent clinical trials have utilized B-lymphocyte-depleting monoclonal antibodies to treat various autoimmune diseases, with encouraging results in those where humoral autoimmunity is clearly important. Surprisingly, recent results in animal models suggest that B-lymphocyte depletion may also be effective in the treatment of T-lymphocyte-mediated autoimmune diseases, such as Type 1 diabetes (T1D). This article reviews the experimental evidence that has uncovered pathogenic as well as regulatory roles for B lymphocytes in the prodrome of T1D and how this information is being used to develop novel therapeutic strategies to treat the disease.
|Authors||Cox, S.L.; Silveira, P. A.;|
|Publisher Name||Expert Review of Clinical Immunology|
|URL link to publisher's version||http://www.expert-reviews.com/doi/abs/10.1586/eci.09.4|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/10362|